Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bio-Path Holdings (NQ: BPTH ) 0.9700 -0.0100 (-1.02%) Streaming Delayed Price Updated: 1:10 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Bio-Path Holdings < Previous 1 2 Next > Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules October 10, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules October 08, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Announces Publication in Biomedicines September 16, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24 September 04, 2024 Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path... Via Newsfile Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors August 21, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Reports Second Quarter 2024 Financial Results August 15, 2024 Conference Call to be Held Today at 8:30 A.M. ET From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 August 08, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Provides Clinical Update and Expansion Plans July 08, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase June 17, 2024 EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END Via FinancialNewsMedia Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase June 17, 2024 From FN Media Group LLC Via GlobeNewswire Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress June 14, 2024 Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules June 05, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24 June 04, 2024 Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate... Via Newsfile Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules June 04, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting June 03, 2024 Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress May 24, 2024 Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Reports First Quarter 2024 Financial Results May 15, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 May 08, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 19, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 18, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Inc. (NASDAQ: BPTH) Near Top of Volume Charts in Thursday Trading April 18, 2024 Via Investor Brand Network Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients April 18, 2024 BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 Protein From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Expands Global Patent Portfolio April 15, 2024 Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Provides 2024 Clinical and Operational Update April 02, 2024 Clinical Advances Across Multiple Programs with Several Milestones From Bio-Path Holdings, Inc. Via GlobeNewswire Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23 March 27, 2024 Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate... Via Newsfile Bio-Path Holdings Reports Full Year 2023 Financial Results March 08, 2024 Conference Call to be Held Today at 8:30 A.M. ET From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024 March 01, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire Bio-Path Holdings Announces 1-for-20 Reverse Stock Split February 21, 2024 Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024 From Bio-Path Holdings, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
